Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 61 results
Author
Title
[
Type
]
Year
Filters:
First Letter Of Last Name
is
H
[Clear All Filters]
Journal Article
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Hassan-Zahraee M
,
Ye Z
,
Xi L
,
Baniecki MLynn
,
Li X
,
Hyde CL
,
Zhang J
,
Raha N
,
Karlsson F
,
Quan J
et al.
. 2021.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
.
Inflamm Bowel Dis.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Battat R
,
Hemperly A
,
Truong S
,
Whitmire N
,
Boland BS
,
Dulai PS
,
Holmer AK
,
Nguyen NH
,
Singh S
,
Casteele NVande
et al.
. 2021.
Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 19(3):511-518.e6.
Lukin DJ
,
Kumar A
,
Hajifathalian K
,
Sharaiha RZ
,
Scherl EJ
,
Longman RS
. 2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
.
Gastroenterology. 159(4):1541-1544.e2.
Battat R
,
Dulai PS
,
Casteele NVande
,
Evans E
,
Hester KD
,
Webster E
,
Jain A
,
Proudfoot JA
,
Mairalles A
,
Neill J
et al.
. 2019.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
.
Inflamm Bowel Dis. 25(2):410-420.
Huang C
,
Haritunians T
,
Okou DT
,
Cutler DJ
,
Zwick ME
,
Taylor KD
,
Datta LW
,
Maranville JC
,
Liu Z
,
Ellis S
et al.
. 2015.
Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.
.
Gastroenterology. 149(6):1575-86.
Huang C
,
Haritunians T
,
Okou DT
,
Cutler DJ
,
Zwick ME
,
Taylor KD
,
Datta LW
,
Maranville JC
,
Liu Z
,
Ellis S
et al.
. 2015.
Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.
.
Gastroenterology. 149(6):1575-86.
Huang C
,
Haritunians T
,
Okou DT
,
Cutler DJ
,
Zwick ME
,
Taylor KD
,
Datta LW
,
Maranville JC
,
Liu Z
,
Ellis S
et al.
. 2015.
Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.
.
Gastroenterology. 149(6):1575-86.
Huang C
,
Haritunians T
,
Okou DT
,
Cutler DJ
,
Zwick ME
,
Taylor KD
,
Datta LW
,
Maranville JC
,
Liu Z
,
Ellis S
et al.
. 2015.
Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.
.
Gastroenterology. 149(6):1575-86.
Huang C
,
Haritunians T
,
Okou DT
,
Cutler DJ
,
Zwick ME
,
Taylor KD
,
Datta LW
,
Maranville JC
,
Liu Z
,
Ellis S
et al.
. 2015.
Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.
.
Gastroenterology. 149(6):1575-86.
Marion JF
,
Waye JD
,
Present DH
,
Israel Y
,
Bodian C
,
Harpaz N
,
Chapman M
,
Itzkowitz S
,
Steinlauf AF
,
Abreu MT
et al.
. 2008.
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.
.
Am J Gastroenterol. 103(9):2342-9.
Chen HJoyce
,
Sun J
,
Huang Z
,
Hou H
,
Arcilla M
,
Rakhilin N
,
Joe DJ
,
Choi J
,
Gadamsetty P
,
Milsom J
et al.
. 2015.
Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.
.
Nat Biotechnol. 33(6):656-60.
Chen HJoyce
,
Sun J
,
Huang Z
,
Hou H
,
Arcilla M
,
Rakhilin N
,
Joe DJ
,
Choi J
,
Gadamsetty P
,
Milsom J
et al.
. 2015.
Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.
.
Nat Biotechnol. 33(6):656-60.
DeFilippis EM
,
Longman R
,
Harbus M
,
Dannenberg K
,
Scherl EJ
. 2016.
Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.
.
Curr Gastroenterol Rep. 18(3):13.
Longman RS
,
Diehl GE
,
Victorio DA
,
Huh JR
,
Galan C
,
Miraldi ER
,
Swaminath A
,
Bonneau R
,
Scherl EJ
,
Littman DR
. 2014.
CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.
.
J Exp Med. 211(8):1571-83.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Gerbarg PL
,
Jacob VE
,
Stevens L
,
Bosworth BP
,
Chabouni F
,
DeFilippis EM
,
Warren R
,
Trivellas M
,
Patel PV
,
Webb CD
et al.
. 2015.
The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.
.
Inflamm Bowel Dis. 21(12):2886-96.
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
Sandborn WJ
,
Feagan BG
,
Loftus EV
,
Peyrin-Biroulet L
,
Van Assche G
,
D'Haens G
,
Schreiber S
,
Colombel J-F
,
Lewis JD
,
Ghosh S
et al.
. 2020.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
.
Gastroenterology. 158(8):2123-2138.e8.
1
(current)
2
3
next ›
last »